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AbstrAct
background Unruptured intracranial aneurysms (UIAs) 
are increasingly diagnosed and are commonly treated 
using endovascular treatment or microsurgical clipping. 
The safety and efficacy of treatments have not been 
compared in a randomised trial. How to treat patients 
with UIAs suitable for both options remains unknown.
Methods We randomly allocated clipping or coiling 
to patients with one or more 3–25 mm UIAs judged 
treatable both ways. The primary outcome was treatment 
failure, defined as: initial failure of aneurysm treatment, 
intracranial haemorrhage or residual aneurysm on 1-year 
imaging. Secondary outcomes included neurological 
deficits following treatment, hospitalisation >5 days, 
overall morbidity and mortality and angiographic results 
at 1 year.
results The trial was designed to include 260 patients. 
An analysis was performed for slow accrual: 136 
patients were enrolled from 2010 through 2016 and 
134 patients were treated. The 1-year primary outcome, 
available for 104 patients, was reached in 5/48 (10.4% 
(4.5%–22.2%)) patients allocated surgical clipping, 
and 10/56 (17.9% (10.0%–29.8%)) patients allocated 
endovascular coiling (OR: 0.54 (0.13–1.90), p=0.40). 
Morbidity and mortality (modified Rankin Scale>2) at 
1 year occurred in 2/48 (4.2% (1.2%–14.0%)) and 
2/56 (3.6% (1.0%–12.1%)) patients allocated clipping 
and coiling, respectively. New neurological deficits 
(15/65 vs 6/69; OR: 3.12 (1.05–10.57), p=0.031), and 
hospitalisations beyond 5 days (30/65 vs 6/69; OR: 8.85 
(3.22–28.59), p=0.0001) were more frequent after 
clipping.
conclusion Surgical clipping or endovascular coiling of 
UIAs did not show differences in morbidity at 1 year. Trial 
continuation and additional randomised evidence will be 
necessary to establish the supposed superior efficacy of 
clipping.
IntroductIon
Unruptured intracranial aneurysms (UIAs) are rela-
tively common, with an estimated prevalence of 
2%–5%.1 They are increasingly diagnosed due to the 
widespread availability of non-invasive imaging.1 2 
An increasing number of patients are undergoing 
aneurysm repair, particularly with coiling, mainly 
to prevent the often devastating effects of subarach-
noid haemorrhage (SAH), but the benefits of any 
preventive treatment have never been proven.3–5
There are two ways to repair aneurysms. Surgical 
clipping is gradually being replaced by less invasive 
endovascular treatment.1 6 For ruptured aneurysms, 
this shift in practice is supported by the results of 
the International Subarachnoid Aneurysm Trial 
(ISAT) that demonstrated improved 1-year clinical 
outcomes with coiling as compared with clipping.7 
However, the results for ruptured aneurysms do 
not apply to UIAs: the added morbidity of surgery 
seen in ISAT cannot be extrapolated to surgery 
for UIAs, as conditions for surgical treatment are 
more favourable in the elective, unruptured setting. 
Furthermore, the two settings differ in fundamental 
clinical aims. In the situation of a ruptured aneu-
rysm, the primary goal of treatment is to ensure 
that the patient survives the acute phase of SAH 
with minimal morbidity and without aneurysm 
rebleeding. In this context, the presence of residual 
or development of recurrent aneurysm, gener-
ally conceded to be more common with aneurysm 
coiling, is less of a concern than with UIA, where the 
primary goal is lifelong protection from aneurysm 
rupture.8 9 Here, the problem of residual or recur-
rent aneurysm may require surveillance imaging, or 
even warrant retreatment with additional risks.10–12
Proponents of surgery believe that it has supe-
rior efficacy and durability compared with coiling. 
Endovascular repair, on the other hand, has the 
appeal of a less invasive procedure and perhaps 
decreased treatment-related morbidity. Neither of 
these claims been demonstrated in a randomised 
trial.12–19 The best available comparative evidence 
are the results of meta-analyses of observation 
studies of outcomes following surgical clipping14 
or endovascular coiling,16 a large international 
registry20 and National Inpatient Sample (NIS) 
database data1-23 but these are subject to the limita-
tions of observational studies.24
There exists significant variability and disagreement 
among clinicians on how best to manage patients with 
UIA suitable for repair with either approach.25
We reasoned that these patients would be best 
managed within the context of a pragmatic trial, with 
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the randomised allocation offering an equal chance of getting the 
best treatment, which for the time being remains unknown. The 
Collaborative UnRuptured Endovascular versus Surgery (CURES) 
study was launched in 2010 to examine trial feasibility and to 
compare angiographic and clinical outcomes following clipping and 
coiling after 1 year.
Methods
CURES is an investigator-led, pragmatic, multicentre randomised 
(1:1) parallel-group trial conducted in four Canadian and one 
European centres. The hypothesis was that ‘Surgical clipping of 
intradural, saccular, UIAs is superior to endovascular manage-
ment in terms of decreasing the number of patients experiencing 
treatment failure from 14% to 3%’.26 The number of patients 
needed to demonstrate this difference was estimated to be 118 
per group (with a statistical power of 0.80 and a two-sided 
type 1 error of 0.05), or 260 patients (to account for loss to 
follow-up and cross-overs). Blinded data were examined by the 
Data Safety Monitoring Committee (DSMC) at preplanned 100 
patient intervals, but there were no prespecified stopping rules. 
Data capture and management were through secure servers 
in compliance with Good Clinical Practice requirements. The 
protocol was approved by all local Institutional Review Boards, 
and all patients provided written informed consent prior to 
participation. Case report forms were simple, and data collected 
parsimonious, in order to facilitate completion by normal care 
personnel. Screening logs were not required by protocol.
Patients
The trial was designed to address the question of the best treat-
ment for patients with UIAs eligible for both endovascular and 
surgical repair. Independent (modified Rankin Scale (mRS) 
score of ≤2) patients 18 years and older with any intradural 
saccular UIAs 3–25 mm in maximal cross-sectional diameter 
were offered participation if they had at least 10 years of life 
expectancy. Aneurysms were excluded if they were thought to 
require endovascular flow diversion or parent vessel occlusion, 
with or without a bypass. Patients with multiple aneurysms 
were not excluded. The protocol was not modified other than 
to include, starting in October 2014, patients with recurrent 
previously treated aneurysms (two patients). The trial involved 
five tertiary neurosurgical centres that offer both clipping and 
coiling (in Canada: Calgary, Edmonton, Montreal and Ottawa; 
in Belgium: Liège).
Interventions
Patients were treated with surgical clipping or endovascular 
treatment as per local practices, with technical details regarding 
treatment left to the individual operators.
Figure 1 Flowchart. mRS, modified Rankin Scale.
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outcome measures
The primary outcome measure of treatment failure was considered 
to have occurred at 1 year with (1) initial failure of aneurysm treat-
ment using the allocated modality; or (2) intracranial haemorrhage 
during follow-up; or (3) a residual or recurrent aneurysm found 
using  Computed Tomographic Angiography (CTA), Magnetic 
Resonance Angiography (MRA) or  Digital Subtraction Angiog-
raphy(DSA) during follow-up. Cross-overs to the other treatment 
arm with no attempt to occlude the aneurysm using the randomly 
allocated modality were not considered treatment failures.
Other endpoints included overall morbidity (mRS>2) and 
mortality at 1 year, new perioperative (30 days) neurological 
deficits (defined as any new weakness, sensory abnormality, 
decreased level of consciousness or cranial nerve deficit), 
perioperative morbidity (mRS>2) measured at discharge, 
peritreatment hospitalisation lasting >5 days and discharge from 
hospital to a location other than home.
Follow-up tests and visits were standard per local practices, 
including neurological examinations, brain imaging studies and a 
functional assessment according to the mRS at discharge, 6 weeks 
and 1 year. A vascular imaging study at 12±2 months to verify 
aneurysm occlusion was expected as standard care, with results 
centrally adjudicated by an independent diagnostic neuroradiol-
ogist (FG). The core lab classified angiographic results at 1 year 
according to a three-tier system (complete occlusion, residual 
neck, residual aneurysm) as reported in reference.10
randomisation
Parallel-group randomisation (1:1) was concealed, generated 
through a web-based platform (MedSciNet). Minimisation 
criteria used were as follows: age>60, aneurysm size≥15 mm 
and posterior circulation location. Posterior communicating 
artery aneurysms were considered to be in the anterior circula-
tion. Randomisation and minimisation functions were tested to 
ensure that the processes were robust.
blinding
In this pragmatic trial comparing open surgical and endovascular 
approaches, blinding to treatment assignment of patients, physi-
cians and outcome assessors was not possible.
statistical analyses
Analyses were performed by a statistician (LT) according to 
protocol. Baseline characteristics were compared between two 
groups using t tests or Fisher’s exact tests, when appropriate. 
For primary and secondary endpoints, binomial proportions 
were estimated by treatment group and 95% CIs constructed 
using the Wilson score method to account for small numbers. 
The primary outcome between the two treatment groups was 
compared using Fisher’s exact test. The OR and associated 95% 
CI were reported. The statistical significance level was set at 0.05 
for a two-sided test. All statistical analyses were conducted using 
R.3.2.2 (R foundations for statistical computing).





Mean age at treatment, year (SD) 56 (8) 57 (7)
Female sex, n (%) 41 (62%) 53 (76%)
 Pretreatment mRS score=0, n (%) 55 (83%) 47 (67%)
  =1, n (%) 10 (15%) 19 (27%)
  =2, n (%) 0 3 (4%)
  No mRS: patients not yet treated 1 (2%) 1 (2%)
  Patients with multiple aneurysms 12 18
Index aneurysm
 Location
Anterior circulation 65 66
  Ophthalmic/paraophthalmic 9 8
  Posterior communicating 7 12
  Carotid terminus 6 8
  MCA bifurcation 18 15
  Anterior communicating 19 13
  Other anterior circulation location 6 10
 Posterior circulation 1 4
 Index aneurysm size (mm), mean (range) 8.7 (3–20) 8.2 (3–23)
  Aneurysm size 3–10 mm 53 53
  Size 11–15 mm 8 12
  Size 16–24 mm 4 3
Recurrent, previously treated index aneurysm 1 1
Symptomatic aneurysms 12 10
  Pain/headache 6 10
  Cranial nerve palsy 2 0
  Stroke/TIA 4 0
 History of previous SAH from another  
aneurysm
7 7
 Hypertension 34 31
Current smoker 26 30
Excessive alcohol 7 3
Positive family history 10 13
treatment
Time from randomisation to treatment, mean 
weeks (SD)
14 (6) 6 (1)
Adherence to assigned treatment, n (%) 63/65 (97%) 66/69 (96%)
Index aneurysm rupture after randomisation, 
prior to treatment
1 0
Additional non-index aneurysms treated at 
same time 12 5
MCA, Middle Cerebral Artery; mRS, modified Rankin Scale; SAH, subarachnoid 
haemorrhage; TIA, transient ischemic attack.
table 2 Primary outcome
Intent-to-treat analysis surgical endovascular
1-year outcome n=48 n=56 or
Treatment failure (composite) 5 10 0.54 (0.13, 1.90), 
p=0.40
Failure to treat aneurysm with 
allocated modality




1 1 1.17 (0.01, 93.44), 
p=1.00
Saccular residual aneurysm 3 6 0.56 (0.09, 2.80), 
p=0.51
As-treated analysis
1-year outcome n=49 n=55
Treatment failure (composite) 5 10






Saccular residual aneurysm 3 6
FU, Follow-Up.
group.bmj.com on August 30, 2017 - Published by http://jnnp.bmj.com/Downloaded from 
666 Darsaut Te, et al. J Neurol Neurosurg Psychiatry 2017;88:663–668. doi:10.1136/jnnp-2016-315433
cerebrovascular disease
roles of the funding source and data integrity
The study was funded by the CIHR (MOP 119554) and spon-
sored by the Centre Hospitalier de l’Université de Montréal. 
Neither funding agency nor sponsor had any part in the study 
design, data collection, analysis or reporting, and no access to 
the data or source documents. The full protocol was published26 
and the latest version is available online (http://www. clinical- 
care- trials. org/ cures- study).
results
From September 2010 to May 2016, 136 patients with 181 
UIAs (136 index aneurysms and 45 additional aneurysms) 
were recruited. On 9 May 2016, the Steering Committee (SC) 
submitted blinded 1-year outcome data on the first 100 patients 
to the DSMC. The DSMC had no concerns related to the 
conduct of the trial. Given the slow accrual, financial commit-
ments to participants and deadlines for funding renewal, the SC 
decided to examine the trial results available to date.
The outcomes of all patients who were registered and 
randomised are presented in the trial profile (figure 1). The 
number of patients with UIAs managed outside the trial cannot 
be provided because eligibility logs were not required per 
protocol. Baseline patient and aneurysm characteristics (table 1) 
were similar, with no statistically significant differences. Of 136 
patients, 63/66 patients that were randomly allocated clipping 
underwent clipping; two were coiled and one patient has not 
been treated. Of the 70 patients randomly allocated coiling, 
66 underwent coiling, 3 patients were clipped and 1 has not 
been treated, leaving 134 patients for safety outcome analysis 
at 6 weeks. Details regarding treatments and complications are 
provided in online supplementary table 4 (see online supplemen-
tary tables).
The 1-year primary outcome data are available for 104/136 
(76.5%) patients (table 2). Ten of 56 patients (17.9% (10.0%–
29.8%)) in the endovascular group and 5 of 48 (10.4% (4.5%–
22.2%)) in the surgical group reached the primary outcome 
of ‘treatment failure’, defined as failure to treat the aneurysm, 
aneurysm remnant at 1 year or intracranial haemorrhage during 
follow-up. The OR of reaching the primary outcome for endo-
vascular coiling versus surgical clipping was 0.54 ((0.13–1.90), 
p=0.40). An as-treated analysis of the primary endpoint gave 
similar results. In the endovascular group, three patients could not 
be treated with coils, one had a fatal treatment-related SAH and six 
had saccular aneurysmal recurrences during follow-up (retreated by 
Figure 2 Functional outcome after endovascular coiling or after surgical clipping of unruptured intracranial aneurysm according to the modified Rankin 
Scale (mRS) score. eVT, endovascular Treatment.
table 3 Secondary outcomes (intent to treat)
clinical outcome surgical n=65 endovascular n=69 p Value
Number of days hospitalised peritreatment, mean (median) (range) 6.7 (5) (2–25) 3.9 (1) (0–122) <0.001
Number of patients hospitalised for >5 days 30 (46.2%) 6 (8.7%) <0.001
Postoperative morbidity (mRS>2) 3/65 (4.6%) 3/69 (4.3%) 1.0
Patients with new neurological deficits following  treatment 16/65 (24.6%) 7/69 (10.1%) 0.038
Discharge location
  Home 59 (91%) 65 (94%) 0.52
  Other hospital 3 (4.6%) 1 (1.4%)
  Rehabilitation centre 2 (3.1%) 2 (2.9%)
  Death 1 (1.5%) 1 (1.4%)
  Morbidity and mortality at 1 year (mRS>2) 2/48 (4.2%) 2/56 (3.6%) 1.0
  Re-treatment of index aneurysm during follow-up 1/65 (1.5%) 2/69 (2.9%) 1.0
Angiographic imaging outcome (1 year) surgical n=48 endovascular n=56
Follow-up imaging result
  Evidence of residual saccular aneurysm 3/48 (6.3%) 6/56 (10.7%) 0.51
  Evidence of residual aneurysm neck 5/48 (10.4%) 11/56 (19.6%) 0.28
mRS, modified Rankin Scale.
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coiling (1), clipping (1) and left untreated (4)). In the surgical group, 
one clipped index aneurysm patient was immediately returned for 
clip removal when the patient awoke hemiparetic. The clip was 
left off the aneurysm. One surgical patient died following aneu-
rysmal rupture the day prior to scheduled treatment and three other 
residual aneurysms were identified during follow-up (re-treated 
with stent-assisted coiling (1) and left untreated (2)). Three patients 
randomised to coiling crossed over to clipping, citing personal 
preference. Two patients crossed over from clipping to coiling, one 
citing personal preference, whereas the other randomised patient 
was crossed over by the surgical team, having changed their mind 
about eligibility for both treatments due to the presence of a calci-
fied aneurysm neck. The five crossed-over patients all had successful 
aneurysm treatment.
Secondary outcomes, including mRS scores at time of 
discharge, 6 weeks and at 1 year of follow-up are presented in 
figure 2 and table 3. New perioperative neurological deficits 
occurred more commonly in patients treated surgically (16/65 
(24.6%; 15.8%–36.3%) vs 7/69 (10.1%; 5.0%–19.5%); OR: 
2.87 (1.02–8.93), p=0.038), as did hospitalisation for more 
than 5 days (30/65 (46.2%; 34.6%–58.1%) vs 6/69 (8.7%; 
4.0%–17.7%); OR: 8.85 (3.22–28.59), p=0.0001). Clinical 
follow-up to 1 year is available in 106 patients: 1/48 (2.0%; 
(0.3%–10.9%)) clipped versus 1/58 (1.7%; (0.3%–9.1%)) coiled 
patients had died, and 1/48 clipped versus 1/58 coiled patients 
had become disabled (mRS>2).
Two patients treated with coiling declined 1-year follow-up 
imaging. At 1 year, 45/48 (93.8%; 83.2%–97.9%) patients allo-
cated surgical clipping and 50/56 (89.3%; 78.5%–95.0%) allo-
cated aneurysm coiling had no evidence of residual saccular 
aneurysm (p=0.49). Details regarding angiographic imaging 
outcomes are available in online supplementary table S5.
dIscussIon
Surgical trials are difficult, particularly when they concern widely 
different but accepted and practiced therapies.27 Although clip-
ping and coiling have been used to prevent the rupture of UIAs 
for decades, there is no direct evidence of clinical benefit from 
either treatment compared with simple observation of these 
lesions. This fundamental question was not addressed by this 
trial. A previous international attempt to compare outcomes of 
coiling and conservative management of UIAs was halted due to 
insufficient recruitment.4 We addressed the next most important 
problem concerning UIAs with a trial comparing the two most 
frequent active management strategies which we hoped would 
be more readily accepted by both candidate patients and treating 
physicians.
Because UIAs rupture infrequently, on the order of 1% per 
year,1 20 a proper comparison of preventive treatments would 
ideally require thousands of patients followed for 5–10 years, 
using a hard clinical outcome such as death and major morbidity 
as a primary endpoint.18 For practical reasons, we started with 
a smaller trial and a more modest objective, using a surrogate 
primary outcome, measured over a shorter 1-year time frame. 
The results of angiography are routinely used by clinicians to 
verify treatment efficacy in individual patients, and they are 
the most common choice of endpoint in trials of aneurysm 
therapy.28–31 Because coiling was reputed but not proven to be 
less morbid initially, and clipping was theoretically more durable, 
what was chosen was a hypothesis that could be verified within a 
feasibly short time frame, yet long enough for patients to recover 
from transient surgical treatment-related morbidity, or for coiled 
aneurysms to recur.
At 1 year, the hypothesised superior efficacy of clipping could 
not be shown, but the target number of patients was not reached 
and some coiled aneurysms are known to recur after 1 year.10
The trial does provide randomised evidence that surgical clip-
ping is associated with longer hospitalisation and more frequent 
treatment-related neurological deficits, as suggested by epide-
miological studies.13 21–23 32 Many of these deficits were mild 
or transient, and did not lead to a difference in mRS scores at 
discharge. At 1 year, death and dependency remained similarly 
infrequent in both treatment groups.
Although less morbid a procedure in the short term, there is 
no guarantee that coiling provides better patient safety over the 
patient’s lifetime. Microsurgical clipping could still prove to be 
better, if delayed rupture occurs more often in recurrent coiled 
aneurysms, or as repeated angiography and re-treatments with 
attendant complications are performed over time.11
Confronted with a slow-recruiting trial, there are two stan-
dard options: stop the trial and report inconclusive results, or 
continue the trial without reporting results for fear of endan-
gering recruitment. This latter option makes sense if there is hope 
for the trial to eventually reach the target number of patients.
In this case, the SC considered neither option to be appro-
priate. The use of clipping is already declining, and accordingly 
so is microsurgical expertise in aneurysm repair.6 33 It would be 
unfortunate to prematurely abandon a surgical treatment that 
could provide better long-term clinical outcomes, if that is the 
case. In the mean time, many centres still offer clipping to some 
patients, but it will become increasingly difficult to justify a 
more invasive intervention if benefits cannot be demonstrated 
in real-world practice. Given the greater initial morbidity associ-
ated with clipping, the burden of the proof is on its practitioners 
to demonstrate that it is associated with long-term benefits. 
This can only be properly done in an Randomized Controlled 
Trial (RCT), which becomes a necessity if we are to provide 
outcome-based neurosurgical care.
The second option, continuing the trial, is thought to require 
concealment of ongoing results, which could be improperly used as 
justification for choosing one treatment over the other, rather than 
continue randomised allocation of management options. For UIAs, 
most clinicians already use non-randomised evidence and opinions 
to justify their choice of one type of management. 1 34 Rather than 
draw premature conclusions for making clinical decisions outside 
the trial, the intent of transparent reporting is to reassure the neuro-
vascular community and funding agencies that randomised trials 
can be implemented in practice, and that patients have acceptable 
outcomes at 1 year with both treatments. These data could also 
contribute to future meta-analyses.35
Although there are a small number of patients and centres, 
limiting the generalisability of the results, the patients in this 
trial had demographic and aneurysm characteristics similar to 
those reported in meta-analyses of UIA clipping and coiling 
outcomes.14 16 Other limitations include the surrogate angio-
graphic endpoint, lack of blinding and the short follow-up. 
Other aspects of this study are intrinsic to the pragmatic 
design choices, which in the spirit of care trials, placed patient 
interests first, and thus required no additional tests, risks, 
visits or costs.36
conclusIon
Surgical clipping or endovascular coiling of UIAs did not show 
differences in morbidity at 1 year. Trial continuation and addi-
tional randomised evidence will be necessary to establish the 
supposed superior efficacy of clipping.
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